Paravalvular Regurgitation after Transcatheter Aortic Valve Replacement: Comparing Transthoracic versus Transesophageal Echocardiographic Guidance
Salim S. Hayek(Rush University Medical Center), Stamatios Lerakis(Emory University), Vasilis Babaliaros(Valve (United States)), José F. Condado(Emory University), Sharon Howell(Emory University), Frank Corrigan(Emory University), Patricia Keegan(Center for Drug Evaluation and Research), Shuai Zheng(Emory University), James P. MacNamara(Texas Health Dallas), Shuang Lin(Emory University), Vinod H. Thourani(Valve (United States))
Cited by 42
Related Papers
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
|JAMA Internal Medicine|2020|1k
First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
|New England Journal of Medicine|2017|657
FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
|The Oncologist|2009|646
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
|JAMA Internal Medicine|2020|555